Leciva 1994 Expectations

12 December 1994

Leciva Praha, the largest producer of pharmaceuticals in the Czech Republic, is expected to achieve a profit of 850 million crowns ($30.3 million) on a turnover of 4 billion crowns in 1994, according to the CTK news agency's Business News.

Leciva, which has a domestic market share of 21%, produces around 180 preparations in 250 medicinal forms. Mainly known for its antibiotic, ampicillin, and flu remedy Paralen, the company sells more than 70% of its production on the Czech market, while 20% is exported to Slovakia and 10% to Western countries. A third of production is accounted for by licensed preparations from international pharmaceutical companies such as Sandoz and Roussel Uclaf.

The company has invested more than 1 billion crowns over the past three years in its modernization. It employs a workforce of 1,480.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight